Wegovy, Mounjaro or Ozempic: which works best, and for whom? Pakistan now makes cheaper local versions, but experts warn these weight-loss and diabetes injections cannot cure the disease.
Lahore: Weekly injections that control blood sugar and melt away weight have become the most talked-about medicines in the world, and Pakistan is now at the center of the boom.
About 34.5 million people in Pakistan live with diabetes, according to 2025 government, WHO, and International Diabetes Federation data, so demand for Ozempic, Wegovy, and Mounjaro is soaring. But which one suits whom, and can they really reverse diabetes?
Same drug, different names
Ozempic and Wegovy both contain semaglutide and are made by Novo Nordisk. Ozempic is approved for type 2 diabetes. Wegovy uses higher doses and is approved for weight loss in people with obesity.
Mounjaro, by Eli Lilly, contains tirzepatide. It acts on 2 gut hormones, GLP-1 and GIP, while semaglutide acts only on GLP-1.
Which one is stronger?
In head-to-head trials, tirzepatide comes out ahead. In the SURPASS-2 study of people with type 2 diabetes, tirzepatide 15mg reduced A1c by 2.46% vs semaglutide 1mg at 1.86%, with weight loss of 12.4 kg vs 6.2 kg. In people with obesity, after 72 weeks, tirzepatide at the maximum dose produced weight reductions of 22% vs 15% for semaglutide.
Who should consider which?
- Ozempic: adults with type 2 diabetes who mainly need sugar control
- Wegovy: adults with obesity, or overweight adults with related health problems, who need weight loss
- Mounjaro: people who need the strongest effect on both sugar and weight
None of these medicines is for type 1 diabetes. Doctors generally avoid them in people who are pregnant or breastfeeding, or who have a history of medullary thyroid carcinoma, MEN 2 syndrome, or pancreatitis. The most common side effects are nausea, diarrhea, and vomiting, which are usually mild to moderate.
Can they reverse diabetes?
Not in the sense of a cure. Large weight loss can push type 2 diabetes into remission, especially in people diagnosed recently. The DiRECT trial showed that sustained weight loss of 15% or more can produce remission in patients with disease duration under 6 years, and these drugs can deliver that much weight loss. However, whether remission persists after stopping medication is uncertain, as weight regain suggests most patients would need ongoing treatment.
Are they available in Pakistan?
Yes. DRAP only allows firms to launch medicines already approved by a stringent regulatory authority in developed nations. Local companies now make their own versions.
Prices in Pakistan
| Medicine | Maker | Price (PKR) |
|---|---|---|
| Ozempic 1 mg | Novo Nordisk | 19,395 |
| Wegovy 0.25 to 2.4 mg | Novo Nordisk | 31,945 to 70,509 |
| Mounjaro (imported) | Eli Lilly | Up to 195,000 |
Sources for the prices: Ozempic 1 mg is listed at Rs. 19,395; Wegovy ranges from Rs. 31,945 for 0.25 mg to Rs. 70,509 for 2.4 mg; one online store lists Mounjaro at Rs. 195,000. Prices vary by pharmacy, and each pen or syringe lasts a different number of weeks, so compare the monthly cost.
The bottom line
These drugs are powerful, but they work best alongside diet and exercise, and only under a doctor’s supervision. Buying from unverified sellers risks counterfeit products.
